Al­ler­gan ties up Na­men­da loose ends with $750M set­tle­ment

Al­ler­gan, which is in process of be­ing swal­lowed by Ab­b­Vie, is clear­ing out the cob­webs. On Mon­day, it agreed to pay $750 mil­lion to set­tle class-ac­tion lit­i­ga­tion sur­round­ing its Alzheimer’s drug Na­men­da.

In the sum­mer of 2014, New York’s then-at­tor­ney gen­er­al Er­ic Schnei­der­man filed an an­titrust law­suit against a unit of Ac­tavis (now Al­ler­gan), al­leg­ing that the com­pa­ny had tak­en il­le­gal steps to de­lay and im­pair gener­ic com­pe­ti­tion for Na­men­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER